Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer's Drug Pipeline on May 23, 2025 Acquisition Agonist Alzheimer 's disease Microglia Neurodegenerative Disorders Phase 2 trials sanofi TREM2 VG-3927 Vigil Neuroscience +